Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV-specific cytokine-induced killer cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral, Intraperitoneal, Intracervical
01
Overview
HPV-specific cytokine-induced killer (CIK) cells are a form of adoptive cell therapy in which a patient's immune effector cells are expanded and activated ex vivo using specific cytokines and then redirected to target human papillomavirus (HPV)-infected or HPV-associated tumor cells. These CIK cells possess both T cell and natural killer (NK) cell properties, enabling them to recognize and kill cancerous or virally infected targets in an MHC-unrestricted manner. The mechanism of action involves the direct cytotoxicity against HPV-infected or transformed cervical cancer cells, often mediated by upregulation of activating receptors such as NKG2D on the CIK/NK-like population, as well as secretion of pro-inflammatory cytokines that enhance anti-tumor immunity[1][2]. This approach is being explored primarily for the treatment of cervical cancer and other malignancies associated with persistent high-risk HPV infection.
- Other names
- HPV-specific CIK cellshuman papillomavirus-specific cytokine-induced killer cells
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on HPV-specific cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV-specific cytokine-induced killer cells.